Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

被引：0
|
作者：
Akio Nakasya
Yuya Hagiwara
Tatsuki Ikoma
Yusuke Kurioka
Toshihiko Matsumoto
Yoshiyuki Yamamoto
Takao Tsuduki
Takeshi Kajiwara
Toshikazu Moriwaki
Tomohiro Nishina
Natsumi Yamashita
Ichinosuke Hyodo
机构：
[1] National Hospital Organization Shikoku Cancer Center,Department of Gastrointestinal Medical Oncology
[2] University of Tsukuba,Department of Gastroenterology, Faculty of Medicine
[3] Kobe City Medical Center General Hospital,Department of Medical Oncology
[4] Himeji Red Cross Hospital,Department of Internal Medicine
[5] National Hospital Organization Shikoku Cancer Center,Section of Cancer Prevention and Epidemiology, Clinical Research Center
来源：
International Journal of Clinical Oncology | 2022年 / 27卷
关键词：
Gastric cancer; Chemotherapy; Albumin-bound paclitaxel; Paclitaxel; Ramucirumab; Propensity score;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：684 / 694
页数：10
相关论文
共 50 条
  • [1] Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)
    Nakasya, Akio
    Hagiwara, Yuya
    Ikoma, Tatsuki
    Kurioka, Yusuke
    Matsumoto, Toshihiko
    Yamamoto, Yoshiyuki
    Tsuduki, Takao
    Kajiwara, Takeshi
    Moriwaki, Toshikazu
    Nishina, Tomohiro
    Yamashita, Natsumi
    Hyodo, Ichinosuke
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (04) : 684 - 694
  • [2] Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer
    Sasaki, Yasutsuna
    Nishina, Tomohiro
    Yasui, Hirofumi
    Goto, Masahiro
    Muro, Kei
    Tsuji, Akihito
    Koizumi, Wasaburo
    Toh, Yasushi
    Hara, Takuo
    Miyata, Yoshinori
    CANCER SCIENCE, 2014, 105 (07) : 812 - 817
  • [3] Risk factors and efficacy outcomes of early-onset severe neutropenia due to paclitaxel or nanoparticle albumin-bound paclitaxel combined with ramucirumab in advanced gastric cancer: a multicenter retrospective cohort study
    Hagiwara, Yuya
    Nakasya, Akio
    Matsumoto, Toshihiko
    Ikoma, Tatsuki
    Yamamoto, Yoshiyuki
    Kurioka, Yusuke
    Tsuduki, Takao
    Kajiwara, Takeshi
    Nishina, Tomohiro
    Yamashita, Natsumi
    Moriwaki, Toshikazu
    Hyodo, Ichinosuke
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, : 2769 - 2778
  • [4] Ramucirumab Plus Paclitaxel as a Second-line Chemotherapy in Older Adults With Advanced Gastric Cancer (YCOG1601)
    Sato, Sho
    Kunisaki, Chikara
    Tamura, Yuko
    Yago, Akikazu
    Kasahara, Kohei
    Sato, Tsutomu
    Kondo, Hiroki
    Kosaka, Takashi
    Akiyama, Hirotoshi
    Endo, Itaru
    ANTICANCER RESEARCH, 2023, 43 (12) : 5663 - 5669
  • [5] Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis
    Ishikawa, Masashi
    Iwasa, Satoru
    Nagashima, Kengo
    Aoki, Masahiko
    Imazeki, Hiroshi
    Hirano, Hidekazu
    Shoji, Hirokazu
    Honma, Yoshitaka
    Okita, Natsuko
    Takashima, Atsuo
    Kato, Ken
    Saruta, Masayuki
    Boku, Narikazu
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 533 - 540
  • [6] Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis
    Masashi Ishikawa
    Satoru Iwasa
    Kengo Nagashima
    Masahiko Aoki
    Hiroshi Imazeki
    Hidekazu Hirano
    Hirokazu Shoji
    Yoshitaka Honma
    Natsuko Okita
    Atsuo Takashima
    Ken Kato
    Masayuki Saruta
    Narikazu Boku
    Investigational New Drugs, 2020, 38 : 533 - 540
  • [7] Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer
    Hironaka S.
    Zenda S.
    Boku N.
    Fukutomi A.
    Yoshino T.
    Onozawa Y.
    Gastric Cancer, 2006, 9 (1) : 14 - 18
  • [8] Multicenter Phase I/II Study of Nivolumab Combined with Paclitaxel Plus Ramucirumab as Second-line Treatment in Patients with Advanced Gastric Cancer
    Nakajima, Takako Eguchi
    Kadowaki, Shigenori
    Minashi, Keiko
    Nishina, Tomohiro
    Yamanaka, Takeharu
    Hayashi, Yuichiro
    Izawa, Naoki
    Muro, Kei
    Hironaka, Shuichi
    Kajiwara, Takeshi
    Kawakami, Yutaka
    CLINICAL CANCER RESEARCH, 2021, 27 (04) : 1029 - 1036
  • [9] The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer
    Jeon, Youngkyung
    Lim, Sung Hee
    Lee, Jeeyun
    Kang, Won Ki
    Jang, Jae Yeon
    Jeong, Sun Young
    Choi, Daeho
    Kim, Seung Tae
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 14 (06) : 2346 - 2353
  • [10] Correlation Between Tumor Response and Survival Outcomes in Patients with Advanced Gastric Cancer Receiving Ramucirumab and Paclitaxel as Second-Line Therapy
    Roviello, Giandomenico
    Martina, Catalano
    Winchler, Costanza
    Aquino, Irene De Gennaro
    Papa, Francesca
    Buttitta, Eleonora
    Rossi, Gemma
    Antonuzzo, Lorenzo
    JOURNAL OF GASTROINTESTINAL CANCER, 2023, 54 (03) : 802 - 808
12345